by age group is: Boomer & Older (born on or before 1964): 18% Gen X (born 1965 to 1980): 44% Millennial (born 1981 to 1996): 32% Gen Z & Younger (Born on or after 1997): 6% The impact of semaglutide on the aesthetics market With patient bodies changing at such an unprecedented scale, we expect widespread impacts on the aesthetics industry as semaglutide adoption continues to grow
Supports modest weight reduction
Adjusting other diabetes medications, especially insulin, may help avoid large, rapid drops in glucose
However, household freezers experience frequent temperature swings from door use and automatic defrost cycles
Unintentional weight loss beyond the expected therapeutic effect, inability to tolerate oral intake, or symptoms preventing normal daily activities all justify clinical reassessment
Practical Guidance for Clinicians and Patients Current evidence suggests an association between semaglutide and NAION, but not definitive proof of causation